Therapeutic Efficacy of ECs Foxp1 Targeting Hif1α-Hk2 Glycolysis Signal to Restrict Angiogenesis

Jingjiang Pi,Jie Liu,Huan Chang,Xiaoli Chen,Wenqi Pan,Qi Zhang,Tao Zhuang,Jiwen Liu,Haikun Wang,Brian Tomlinson,Paul Chan,Yu Cheng,Zuoren Yu,Lin Zhang,Zhenlin Zhao,Zhongmin Liu,Yuzhen Zhang
DOI: https://doi.org/10.1016/j.redox.2024.103281
IF: 11.4
2024-01-01
Redox Biology
Abstract:Endothelial cells (ECs) rely on glycolysis for energy production to maintain vascular homeostasis and the normalization of hyperglycolysis in tumor vessels has recently gained attention as a therapeutic target. We analyzed the TCGA database and found reduced Foxp1 expression in lung carcinoma. Immunostaining demonstrated reduced expression more restricted at tumor vascular ECs. Therefore, we investigated the function and mechanisms of Foxp1 in EC metabolism for tumor angiogenesis required for tumor growth. EC-Foxp1 deletion mice exhibited a significant increase of tumor and retinal developmental angiogenesis and Hif1α was identified as Foxp1 target gene, and Hk2 as Hif1α target gene. The Foxp1-Hif1α-Hk2 pathway in ECs is important in the regulation of glycolytic metabolism to govern tumor angiogenesis. Finally, we used genetic deletion of EC-Hif1α and RGD-peptide nanoparticles EC target delivery of Hif1α/Hk2-siRNAs to knockdown gene expression which reduced the tumor EC hyperglycolysis state and restricted angiogenesis for tumor growth. This study advances our understanding of EC metabolism for tumor angiogenesis, and meanwhile provides evidence for future therapeutic intervention of hyperglycolysis in tumor ECs for suppression of tumor growth.
What problem does this paper attempt to address?